CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 72 enrolled
Drug / intervention
Liraglutide for 26 weeks +1 moredrug
Likely dose
Liraglutide for 26 weeks 1,8mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02073929
NCT02073929Phase 4Completed
CompareCT.gov

A Randomised, Double-blind, Placebo-controlled Study of the Effect of Liraglutide in Polycystic Ovary Syndrome on Risk Markers of Vascular Thrombosis.

Jens Faber·interventional·Posted Feb 28, 2014·Updated Feb 28, 2019

In Brief

A Phase 4 clinical trial evaluating Liraglutide for 26 weeks and placebo for Polycystic Ovary Syndrome and Cardiovascular Disease. Completed, enrolled 72 participants across 3 sites.

Detailed Summary

Polycystic ovary syndrome (PCOS) affects 5-10% of women in fertile age. PCOS is associated with metabolic syndrom, diabetes and and increased risk og cardiovascular disease. The study investigates the effect af intervention with GLP-1-analog on risk markers of cardiovascular disease in women with PCOS. 70 women will be included in af RCT. Hypothesis: GLP-1-analog treatment in women with PCOS (without diabetes) will result in a beneficial reduction in risk markers of vascular thrombosis and early cardiovascular disease.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPolycystic Ovary Syndrome, Cardiovascular Disease
CountriesDenmark
Collaborators--

Timeline

Phase 4CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedFeb 28, 2014
Enrollment StartMar 1, 2014
Primary CompletionDec 1, 2015
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 12.3 years ago

Interventions

Liraglutide for 26 weeksdrug

GLP-1-analogue Liraglutide s.c. 1,8mg daily for 26 weeks

placebodrug

Placebo s.c. daily for 26 weeks